Edesa Biotech, Inc. (EDSA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Edesa Biotech, Inc. (EDSA) is up 438.0% since the beginning of the year. At $8 per share, EDSA is trading 62.4% below its 52-week high of $20. Investors who bought $1,000 worth of EDSA shares 5 years ago would now be looking at an investment worth $199.

Edesa Biotech, Inc. (EDSA) has returned 438.03% so far this year and 282.00% over the past 12 months. Over the last ten years, EDSA has returned -40.30% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.

Based on dividend-adjusted daily data since Nov 5, 2015, EDSA's average daily return is +0.03%, while the average monthly return is +0.03%. At this rate, an investment would double in approximately 192.6 years.

Historically, 38% of months were positive and 63% were negative. The best month was Apr 2026 with a return of +249.4%, while the worst month was May 2018 at -62.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, EDSA closed higher 43% of trading days. The best single day was Sep 20, 2021 with a return of +102.7%, while the worst single day was Jan 17, 2023 at -42.1%.

Edesa Biotech, Inc. has an annualized alpha of -1.89%, beta of 0.71, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 05, 2015.

• This stock participated in 119.79% of S&P 500 Index downside but only -82.99% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

EDSA ranks 88 for risk / return — in the top 88% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Edesa Biotech, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Edesa Biotech, Inc. was 99.97%, occurring on Feb 20, 2026. The portfolio has not yet recovered.

The current Edesa Biotech, Inc. drawdown is 99.72%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Edesa Biotech, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Edesa Biotech, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.